Navigation Links
Dutasteride not a cost-effective way to prevent prostate cancer in some men
Date:2/8/2011

DALLAS Feb. 8, 2011 The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

In a study available in the January issue of Cancer Prevention Research, investigators found that the medication, at an annual cost of $1,400, is impractical when compared to the marginal impact on survival and quality of life in at-risk groups. The drug is indicated for the treatment of enlarged prostates but also is widely prescribed for chemoprevention.

"Because prostate cancer is the most common cancer in men, the implications of this data are significant since there could be millions of men who would be eligible for anti-cancer drugs," said Dr. Yair Lotan, associate professor of urology at UT Southwestern. "Prior to instituting a chemoprevention strategy to a large population, the utility and cost need to be well understood. Whether a medication improves survival, how it affects quality of life, and what its financial implications will be are all critical issues. Because dutasteride typically is prescribed for the lifetime of the patient, and therefore taken daily for decades, the cost issue is particularly relevant."

Prior research has shown that dutasteride reduced the relative risk of prostate cancer over a four-year period by 22.8 percent, but questions have remained about its cost-effectiveness. The current study analyzed the lifetime health-related costs of the drug in patients at greater risk of developing prostate cancer and compared them to other factors, such as quality and length of life.

Dr. Lotan and his colleague, Dr. Robert Svatek of UT Health Science Center at San Antonio, used a Markov probability model to compare the lifetime cost of taking dutasteride with no therapy. They used data from a previous trial and studies that evaluated outcomes of patients with prostate cancer, including treatment-related complications to create the model. The primary outcome was measured in quality-adjusted life years (QALY), which takes into account both quality and quantity of life.

"The study found that dutasteride was not cost-effective for chemoprevention unless and until a strategy is developed for targeting very high-risk patients and the cost of the drug decreases," said Dr. Lotan. "For the average man, the drug provides minimal survival benefits, and the reduction on treatment-related complications does not compensate for the high costs of every man taking the drug for many years."


'/>"/>

Contact: Rachel Skei Donihoo
rachel.donihoo@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. European Urology: Editorial about REDUCE trial underlines value of dutasteride
2. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
3. Web-based questionnaire can be cost-effective tool for survey responses
4. Testing African couples for HIV is cost-effective prevention strategy
5. Wider statin use could be cost-effective preventive measure, Stanford study finds
6. Centralized health care more cost-effective, offers better access to preventive services
7. Trauma center care cost-effective
8. UNC physician authors editorial on cost-effectiveness study for colon cancer screening
9. Colorectal cancer screening in Canada is cost-effective
10. Antiviral therapy during compensated cirrhosis most cost-effective approach
11. Hospital Focus 5 Announces Contract with Connecticut Hospital to Improve Quality, Productivity and Cost-Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... MICHIGAN (PRWEB) , ... February 22, 2017 , ... ... analysis of issues related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, ... known as one of a small number of neurosurgeons in Michigan performing minimally ...
(Date:2/22/2017)... ... 2017 , ... Michael J. Hennessy Associates, Inc. (MJH Associates), ... professionals and other key stakeholders with an array of valuable resources, Healthcare Analytics ... announced Michael J. Hennessy, Jr., president of MJH Associates. , In making ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the ... event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth ... For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a ... PTSD. , Established in 1977, our organization was at the forefront in working ... to civilian life were evident and served as the catalyst for the establishing ...
(Date:2/22/2017)... Lexington, Kentucky (PRWEB) , ... February 22, 2017 ... ... the Journal of Patient Safety, patient advocates stress that the patient context (age, ... and not used as reasons to mitigate their occurrence. In addition, ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... According to a new market research report "Process ... and Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO ... market is poised to reach USD 3.30 Billion by 2021 from USD ... 2021. Continue Reading ... ...
(Date:2/22/2017)... -- Des scanners sur smartphone destinés aux professionnels de la ... , au Moyen-Orient et en Afrique  ... Clarius Mobile Health , une société de santé numérique dont ... Canada , a annoncé aujourd,hui qu,elle a reçu la certification ... C3 et L7, destinés à être utilisés par des professionnels de la ...
(Date:2/21/2017)... , Feb. 21, 2017 ... specialized versions are used to monitor physiological signs. These ... remote patient monitors. Remote patient monitoring is one of ... patient monitoring equipment in the market. Hence, vendors are ... smartphones and applications, which can send test results on ...
Breaking Medicine Technology: